Laboratory Characteristics in Chronic Atrophic Acrodermatitis
Not Applicable
- Conditions
- Chronic Atrophic Acrodermatitis
- Interventions
- Registration Number
- NCT02147262
- Lead Sponsor
- University Medical Centre Ljubljana
- Brief Summary
The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with chronic atrophic dermatitis to gain better insight into pathogenesis of chronic infection with Borrelia burgdorferi sensu lato.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- chronic atrophic dermatitis in patients >18 years
Exclusion Criteria
- none
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ACA-doxy 14 days doxycycline orally, 100 mg, bid, 14 days patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days ACA-doxy 28 days doxycycline orally, 100 mg, bid, 28 days patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days
- Primary Outcome Measures
Name Time Method inflammatory proteins in patients with chronic atrophic dermatitis up to 24 months The inflammatory immune profiles will be assessed using Luminex to measure the expression of cytokines and chemokines representative of innate and adaptive TH1, TH2, TH17, and B cell responses.
- Secondary Outcome Measures
Name Time Method clinical characteristics of patients with chronic atrophic dermatitis treated with doxycycline for 14 or 28 days at enrollment, at 2, 6 12 and 24 months follow-up
Trial Locations
- Locations (1)
UMC Ljubljana, Department of Infectious Diseases
🇸🇮Ljubljana, Slovenia